Apellis Pharmaceuticals Inc expected to post a loss of 86 cents a share - Earnings Preview

Apellis Pharmaceuticals

30/10/2023 17:56

* Apellis Pharmaceuticals Inc  APLS.OQ   APLS.O  is expected
to show a rise in quarterly revenue when it reports  results 
    * The Waltham Massachusetts-based  company is expected to
report 
a 347.6% increase in revenue to $98.726 million from $22.06
million a year ago, according to the mean estimate from 12
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Apellis
Pharmaceuticals
Inc is for a loss of 86 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Apellis
Pharmaceuticals Inc is $70​, above​ its last closing price
of $47.54. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -1.32       -1.32      -1.02     Beat    22.9
 Mar. 31 2023  -1.50       -1.46      -1.56     Missed  -6.5
 Dec. 31 2022  -1.57       -1.57      -1.50     Beat    4.3​
 Sep. 30 2022  -1.46       -1.45      -1.75     Missed  -20.4
 ​​Jun.        -1.34       -1.36      -1.46     Missed  -7
 30 2022                                                
 Mar. 31 2022  -1.28       -1.32      -1.42     Missed  -7.6​
 Dec. 31 2021  -1.48       -1.54      -1.61     Missed  -4.7
 Sep. 30 2021  -1.75       -1.70      -2.28     Missed  -34.4
 This summary was machine generated October 30 at 17:56 GMT.  All
figures in US dollars  unless otherwise stated